Nektar Therapeutics buy Rodman & Renshaw
Start price
28.06.24
/
50%
€1.19
Target price
28.06.25
€1.87
Performance (%)
15.52%
Price
20:49
€1.38
Summary
This prediction is currently active. The prediction currently has a performance of 15.52%. This prediction currently runs until 28.06.25. The prediction end date can be changed by Rodman___Renshaw at any time. Rodman___Renshaw has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Nektar Therapeutics | 11.304% |
| iShares Core DAX® | 0.559% |
| iShares Nasdaq 100 | -0.854% |
| iShares Nikkei 225® | 1.291% |
| iShares S&P 500 | 0.492% |
Comments by Rodman___Renshaw for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $2.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat